Neisseria Meningitidis Factor H Binding Protein

CHEMBL6068499 Phase 4 ได้รับการอนุมัติ Vaccine component
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A vaccine antigen from Neisseria meningitidis that mimics a bacterial surface protein used to evade the immune system, included in meningococcal B vaccines to generate protective immunity. Antibodies against this protein prevent the bacteria from surviving in the bloodstream.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A vaccine antigen from Neisseria meningitidis that mimics a bacterial surface protein used to evade the immune system, included in meningococcal B vaccines to generate protective immunity. Antibodies against this protein prevent the bacteria from surviving in the bloodstream.

Yes, Neisseria Meningitidis Factor H Binding Protein is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068499. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.